Introduction
StemCyte founded in 1997 and estabilished operations in the United States and Taiwan. In the past 20 years, StemCyte has built nearly 40,000 units of public cord blood bank to provide adequate and stable cellular materials. We have provided more than 2,500 cord blood units to 350 transplant centers around the world. StemCyte is focused on expanding the applications of cell therapy and developing cell therapy products and services. Our core business includes Cell Therapies, Cellular Materials Supply, Cell Products and Services.
Features / strengths
StemCyte's HPC-cord blood product, RegeneCyte®, has been accepted for the biologics license quality review with the US FDA. And our cell therapy pipeline includes two US FDA-approved Phase II clinical trials and one TFDA-approved Phase I clinical trial.
Specification in detail
Cell Therapies
Pipeline includes two US FDA-approved Phase II clinical trials and one TFDA-approved Phase I clinical trial.
